S-1/A: Cingulate Inc. Files Amendment No. 2 to Form S-1 for Potential $4.7 Million Stock Resale by Lincoln Park Capital

Cingulate Inc. has filed an amendment to its Form S-1 registration statement to register an additional 1,500,000 shares for resale by Lincoln Park Capital, potentially raising up to $4.7 million.

Summary

• Cingulate Inc. has filed Amendment No. 2 to its Form S-1 registration statement with the SEC.
• This amendment aims to register an additional 1,500,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC.
• These shares are part of a purchase agreement where Cingulate may sell up to $12.0 million of its common stock to Lincoln Park.
• As of the date of the prospectus, $7,286,779.32 of shares have already been issued and sold to Lincoln Park.
• Cingulate will not receive any proceeds from the resale of shares by Lincoln Park, but may receive up to $4,713,220.68 from the sale of Purchase Shares to Lincoln Park.
• The company intends to use any proceeds from the sale of shares to Lincoln Park for research and development, commercialization of CTx-1301, working capital, capital expenditures, and general corporate purposes.
• The last reported sale price of Cingulate's common stock on Nasdaq on September 24, 2024, was $5.01 per share.
• Cingulate is classified as an emerging growth company, which allows for reduced public company reporting requirements.
• The company effected a 1-for-12 reverse stock split on August 9, 2024.
• As of September 24, 2024, there were 3,044,165 shares of common stock issued and outstanding, of which 2,937,688 shares of common stock are held by non-affiliates of our company.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily outlining the details of a stock resale agreement. While the potential capital raise is positive, the dilution risk and speculative nature of the investment temper the overall sentiment.

Positives

• The potential capital injection of up to $4,713,220.68 can support ongoing research and development efforts.
• The Purchase Agreement provides flexibility in accessing capital markets as needed.
• The company retains control over the timing and amount of stock sales to Lincoln Park.
• Cingulate's emerging growth company status allows for reduced reporting requirements, potentially saving costs.
• Shareholder approval has been obtained to issue shares to Lincoln Park exceeding 19.99% of outstanding shares.

Negatives

• The sale of shares to Lincoln Park will dilute existing stockholders' ownership.
• The market price of Cingulate's common stock could decrease due to the sale of shares by Lincoln Park.
• The company's reliance on Lincoln Park for funding may limit its ability to access capital from other sources.
• The Purchase Agreement includes restrictions on the company's ability to sell shares to Lincoln Park, including the Beneficial Ownership Cap.
• The company may need to register additional shares for resale to receive the full $4,713,220.68 remaining available under the Purchase Agreement, causing further dilution.

Risks

• Investment in Cingulate's securities is highly speculative and involves a high degree of risk.
• The company's lack of operating history and need for additional capital pose significant risks.
• The company's ability to obtain regulatory approvals for its product candidates is uncertain.
• The company's dependence on the Lincoln Park transaction for funding exposes it to market volatility.
• The company's management has broad discretion over the use of proceeds, which may not yield favorable returns.

Future Outlook

The company may sell shares of its common stock to Lincoln Park from time to time over a 36-month period, subject to certain limitations and conditions, to raise additional capital for research and development, commercialization activities, and general corporate purposes.

Industry Context

The document mentions the ADHD treatment market, with an estimated US market size of over $23 billion as of November 2023, of which $18.6 billion is attributable to stimulants. This highlights the potential market for Cingulate's ADHD medications.

Stakeholder Impact

• Existing stockholders will experience dilution of their ownership.
• The company may be able to fund further research and development efforts.
• The market price of Cingulate's stock may be affected by the resale of shares by Lincoln Park.

Next Steps

• The SEC must declare the registration statement effective.
• Cingulate may then, at its discretion, offer shares to Lincoln Park under the Purchase Agreement.
• Lincoln Park may then resell those shares in the open market.

Key Dates

Keywords

Lincoln Park Capital, common stock, registration statement, purchase agreement, Cingulate, shares, resale, offering, securities, dilution, financing, capital